Company: DMAC
Filing Date: 2025-08-22
Form Type: 424B2
Source: 0001437749-25-027557
Chunk: 19

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-22
Form: 424B2
Chunk 19
---
 purpose.

<div align='center'>S-12

DIVIDEND POLICY</div>

We have never declared or paid any cash dividends on our common shares and do not anticipate paying any cash dividends in the foreseeable future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business. Additionally, we may in the future become subject to contractual restrictions on, or prohibitions against, the payment of dividends. Subject to the foregoing, the payment of cash dividends in the future, if any, will be at the discretion of our Board of Directors and will depend upon such factors as earnings levels, capital requirements, our overall financial condition and any other factors deemed relevant by our Board of Directors. As a result, our shareholders will likely need to sell their common shares to realize a return on their investment and may not be able to sell their common shares at or above the price paid for them.

<div align='center'>S-13

DILUTION</div>

If you invest in our common shares in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per common share and the as adjusted net tangible book value per share of our common shares immediately after this offering. Net tangible book value per common share is determined at any date by subtracting our total liabilities from the amount of our total tangible assets (total assets less intangible assets) and dividing the difference by the number of our common shares deemed to be outstanding at that date.

Our net tangible book value as of June 30, 2025 was approximately $27.2 million, or $0.63 per common share, based on 43,072,488 common shares outstanding as of June 30, 2025. After giving effect to the sale of ourcommon shares in the aggregate amount of $100.0 million in this offering at an assumed offering price of $5.76 per common share, the last reported sale price of our common shares on The Nasdaq Capital Market on August 19, 2025, and after deducting commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2025 would have been $124.7 million, or $2.06 per common share. This amount represents an immediate increase in net tangible book value of $1.43 per common share to existing shareholders and an immediate dilution in net tangible book value of $3.70 per common share to new investors purchasing common shares